{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:19:43Z","timestamp":1768547983563,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,8,24]],"date-time":"2013-08-24T00:00:00Z","timestamp":1377302400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s00277-013-1880-4","type":"journal-article","created":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T07:00:43Z","timestamp":1377241243000},"page":"1521-1528","source":"Crossref","is-referenced-by-count":27,"title":["CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial"],"prefix":"10.1007","volume":"92","author":[{"name":"for the German High Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Binder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ziepert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pfreundschuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"D\u00fchrsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Eimermacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Aldaoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rosenwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Truemper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,24]]},"reference":[{"key":"1880_CR1","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","volume":"117","author":"FM Foss","year":"2011","unstructured":"Foss FM, Zinzani PL, Vose JM et al (2011) Peripheral T-cell lymphoma. Blood 117:6756\u20136767","journal-title":"Blood"},{"key":"1880_CR2","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL et al (2011) Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117:3402\u20133408","journal-title":"Blood"},{"key":"1880_CR3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124\u20134130","journal-title":"J Clin Oncol"},{"key":"1880_CR4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3960\/jslrt.51.29","volume":"51","author":"T Akagi","year":"2011","unstructured":"Akagi T, Takahashi N, Yamaguchi K et al (2011) Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology Forum. J Clin Exp Hematop 51:29\u201335","journal-title":"J Clin Exp Hematop"},{"key":"1880_CR5","first-page":"76","volume":"92","author":"C Gisselbrecht","year":"1998","unstructured":"Gisselbrecht C, Gaulard P, Lepage E et al (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA). Blood 92:76\u201382","journal-title":"Blood"},{"key":"1880_CR6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"MA Shipp","year":"1993","unstructured":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project, Shipp MA, Harrington DP et al (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329:987\u2013994","journal-title":"N Engl J Med"},{"key":"1880_CR7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11899-011-0100-3","volume":"6","author":"KJ Savage","year":"2011","unstructured":"Savage KJ (2011) Update: peripheral T-cell lymphomas. Curr Hematol Malig Rep 6:222\u2013230","journal-title":"Curr Hematol Malig Rep"},{"key":"1880_CR8","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Trumper L, Ziepert M et al (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116:3418\u20133425","journal-title":"Blood"},{"key":"1880_CR9","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","volume":"20","author":"P Corradini","year":"2006","unstructured":"Corradini P, Tarella C, Zallio F et al (2006) Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20:1533\u20131538","journal-title":"Leukemia"},{"key":"1880_CR10","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2002.02.125","volume":"20","author":"C Gisselbrecht","year":"2002","unstructured":"Gisselbrecht C, Lepage E, Molina T et al (2002) Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20:2472\u20132479","journal-title":"J Clin Oncol"},{"key":"1880_CR11","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/annonc\/mdp211","volume":"20","author":"M Nickelsen","year":"2009","unstructured":"Nickelsen M, Ziepert M, Zeynalova S et al (2009) High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 20:1977\u20131984","journal-title":"Ann Oncol"},{"key":"1880_CR12","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/annonc\/mdh471","volume":"15","author":"N Mounier","year":"2004","unstructured":"Mounier N, Gisselbrecht C, Briere J et al (2004) All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA). Ann Oncol 15:1790\u20131797","journal-title":"Ann Oncol"},{"key":"1880_CR13","first-page":"218","volume":"26","author":"C Kyriakou","year":"2008","unstructured":"Kyriakou C, Canals C, Goldstone A et al (2008) High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26:218\u2013224","journal-title":"J Clin Oncol"},{"key":"1880_CR14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","volume":"79","author":"J Rodriguez","year":"2007","unstructured":"Rodriguez J, Conde E, Gutierrez A et al (2007) Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 79:32\u201338","journal-title":"Eur J Haematol"},{"key":"1880_CR15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, Rudiger T, Geissinger E et al (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27:106\u2013113","journal-title":"J Clin Oncol"},{"key":"1880_CR16","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F D\u2019Amore","year":"2012","unstructured":"D\u2019Amore F, Relander T, Lauritzsen GF et al (2012) Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 30:3093\u20139","journal-title":"J Clin Oncol"},{"key":"1880_CR17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","volume":"22","author":"L Ginaldi","year":"1998","unstructured":"Ginaldi L, De MM, Matutes E et al (1998) Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 22:185\u2013191","journal-title":"Leuk Res"},{"key":"1880_CR18","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.10767","volume":"92","author":"PP Piccaluga","year":"2007","unstructured":"Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA (2007) Expression of CD52 in peripheral T-cell lymphoma. Haematologica 92:566\u2013567","journal-title":"Haematologica"},{"key":"1880_CR19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1385\/MO:23:1:17","volume":"23","author":"CE Dearden","year":"2006","unstructured":"Dearden CE (2006) T-cell prolymphocytic leukemia. Med Oncol 23:17\u201322","journal-title":"Med. Oncol"},{"key":"1880_CR20","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","volume":"101","author":"J Lundin","year":"2003","unstructured":"Lundin J, Hagberg H, Repp R et al (2003) Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome. Blood 101:4267\u20134272","journal-title":"Blood"},{"key":"1880_CR21","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","volume":"103","author":"G Enblad","year":"2004","unstructured":"Enblad G, Hagberg H, Erlanson M et al (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103:2920\u20132924","journal-title":"Blood"},{"key":"1880_CR22","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s10637-010-9523-2","volume":"30","author":"SJ Kim","year":"2012","unstructured":"Kim SJ, Kim K, Park Y et al (2012) Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Invest New Drugs 30:368\u2013375","journal-title":"Invest New Drugs"},{"key":"1880_CR23","first-page":"702","volume":"90","author":"PL Zinzani","year":"2005","unstructured":"Zinzani PL, Alinari L, Tani M et al (2005) Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 90:702\u2013703","journal-title":"Haematologica"},{"key":"1880_CR24","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"B Cheson","year":"1999","unstructured":"Cheson B, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphoma. J Clin Oncol 17:1244\u20131253","journal-title":"J Clin Oncol"},{"key":"1880_CR25","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/annonc\/mdg249","volume":"14","author":"A Wunderlich","year":"2003","unstructured":"Wunderlich A, Kloess M, Reiser M et al (2003) Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin\u2019s lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL). Ann Oncol 14:881\u2013893","journal-title":"Ann Oncol"},{"key":"1880_CR26","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","volume":"110","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Zaja F, Patti C et al (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316\u20132323","journal-title":"Blood"},{"key":"1880_CR27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","volume":"60","author":"JG Kim","year":"2007","unstructured":"Kim JG, Sohn SK, Chae YS et al (2007) Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 60:129\u2013134","journal-title":"Cancer Chemother Pharmacol"},{"key":"1880_CR28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/10428190903580402","volume":"51","author":"E Weidmann","year":"2010","unstructured":"Weidmann E, Hess G, Chow KU et al (2010) A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk Lymphoma 51:447\u2013455","journal-title":"Leuk Lymphoma"},{"key":"1880_CR29","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","volume":"22","author":"HC Kluin-Nelemans","year":"2011","unstructured":"Kluin-Nelemans HC, van Marwijk KM, Lugtenburg PJ et al (2011) Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol 22:1595\u20131600","journal-title":"Ann Oncol"},{"key":"1880_CR30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","volume":"151","author":"A Simon","year":"2010","unstructured":"Simon A, Peoch M, Casassus P et al (2010) Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Brit J Haematol 151:159\u2013166","journal-title":"Brit J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-013-1880-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1880-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1880-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T15:45:17Z","timestamp":1563723917000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-013-1880-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,24]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["1880"],"URL":"https:\/\/doi.org\/10.1007\/s00277-013-1880-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,24]]}}}